Concentric Medical commences TREVO Study of Stentriever technology in ischemic stroke patients

Concentric Medical, Inc., the global leader in acute ischemic stroke intervention, today announced the start of the TREVO Study.  The first patients were enrolled and successfully treated at the Hospital Clinic de Barcelona by the Neuroradiology team of Drs. Juan Macho and Jordi Blasco.

The TREVO Study (Thrombectomy REvascularization of large Vessel Occlusions in acute ischemic stroke) is the first to evaluate Stentriever™ technology in a European, multicenter, prospective trial.  TREVO is designed to assess the ability of the Trevo System to remove the blood clots that cause strokes and to restore blood flow to the brain. Additionally, functional outcomes at 90 days will be collected.  Professor Olav Jansen, Head of Interventional Neuroradiology at Universitatsklinikum Schleswig-Holstein, and Professor Nils Wahlgren, Professor of Neurology at Karolinska University Hospital, are co-Principal Investigators of the Study.

Following the treatment of the first patients enrolled into the TREVO Study, Juan Macho, MD, PhD. said, "The Trevo™ System represents a new treatment option for ischemic stroke patients.  It is easy and fast to use and this is essential in the acute stroke setting because a patient's brain is at risk.  I have found the Trevo to be remarkably effective."

Maria Sainz, President and CEO of Concentric Medical, commented on the importance of the study, "Treatment of the first patients in the TREVO Study is a key milestone that demonstrates Concentric's continued commitment to advancing acute stroke intervention.  The TREVO Study will provide prospective multi-center clinical evidence that will accelerate adoption of this new technology for acute ischemic stroke patients."  She added, "European physicians have been pioneers in investigating the clinical possibilities of stentriever technology, so we are excited to conduct our first study with our newest device, Trevo, in Europe."  

SOURCE Concentric Medical, Inc.